Drug intelligence / Profile preview

dithranol

Development stage
Phase 4
Modality
Small Molecules
Administration
Topical
01

Overview

Dithranol (also known as anthralin) is a synthetic small molecule used topically for the treatment of chronic plaque psoriasis. It works by slowing down the rapid proliferation of skin cells characteristic of psoriasis and has anti-inflammatory properties. The drug accumulates in mitochondria where it interferes with cellular energy supply—likely through oxidation that releases free radicals—impeding DNA replication and thus reducing excessive cell division in psoriatic plaques. Dithranol may also reduce elevated cGMP levels seen in psoriasis and induce lipid peroxidation while lowering endothelial adhesion molecules. It is available as creams or ointments at various strengths (typically 0.1–4%) and is applied directly to affected areas for short contact or overnight therapy. Dithranol can cause local irritation and stains skin/clothing but does not have systemic side effects typical of some other antipsoriatic agents[1][2][3][5][6].

Brand names
DrithocremeZithranolZithranol-RRDritho-Creme HPDritho-ScalpPsoriatecMicanol CreamAnthraforte 2%Anthraforte 3%AnthrascalpDithrocream
Other names
dithranolanthralin

Beyond the preview

Go deeper on dithranol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dithranol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call